BioGenes joins EU’s cNEUPRO dementia project

Partnership

Antibody specialist BioGenes GmbH has been chosen as a new partner of cNEUPRO, the EU-funded research project that aims to uncover novel biomarkers for neurodegenerative diseases that can form the basis of improved early and differential diagnosis of Alzheimer’s disease.

BioGenes will provide laboratory facilities and personnel to develop specific monoclonal antibodies against novel neurochemical dementia biomarkers in blood and cerebrospinal fluid that have been identified during the project. Apart from being used in diagnostics, these antibodies will also have potential as therapeutic agents.

Reliable differential clinical diagnosis of very early dementia stages is crucial for choosing the most effective therapy. Recent research has demonstrated that identifying dementia-related biomarkers in cerebrospinal fluid can improve early and differential diagnosis of dementias.

cNEUPRO will establish European standard operation procedures and set up the first reference centres in Portugal and Hungary. The project involves nineteen biotech and bioinformatics companies, as well as leading clinical and proteomics dementia research centres.